Target multifunctional anti-embolism fusion protein as well as preparation method and application thereof

Abstract

The invention belongs to the technical field of genetic engineering, relating to a target multifunctional anti-embolism fusion protein an amino acid sequence of which is as shown in SEQ ID NO.1. The invention also relates to a gene for encoding the fusion protein, a recombinant expression vector containing the gene, a transformant containing the recombinant expression vector and a method for preparing the fusion protein. The fusion protein can reasonably splice human antibacterial peptide LL-37, leech peptide Hirudin-12, Agkistrodon acutus peptide (AAP), arginine-glycin-aspartate (RGD) and human blood coagulation factor Xa identification sites, so that the functions among a target component, an antibacterial component, a thrombin resisting component and a platelet aggregation resisting component are complementary and in synergistic effect; and the fusion protein can well exert target anti-inflammatory and anticoagulation activities at a thrombus position, and simultaneously can repair a vessel endothelial cell, can commonly inhibit the formation and development of thrombus by virtue of multiple ways, and can be used for preparing a medicament for preventing and treating thrombotic diseases.

Description

technical field [0001] The invention belongs to the technical field of genetic engineering, and relates to a fusion protein, in particular to a targeted multifunctional antithrombotic fusion protein, a method for preparing the fusion protein by using genetic engineering technology, and the application of the fusion protein in medicine. Background technique [0002] In recent years, the incidence of cardiovascular and cerebrovascular thrombotic diseases such as atherosclerosis and deep vein thrombosis has increased year by year, seriously endangering human health. Since thrombosis is an important pathogenic factor of such diseases, the core of prevention and treatment of such diseases is antithrombotic, including inhibition of thrombosis and thrombolysis. At present, the clinically used antithrombotic drugs have disadvantages such as poor tissue specificity and many adverse reactions to varying degrees, which can easily lead to clinical complications, aggravate the patient's ...

AI Technical Summary

Problems solved by technology

However, for a long time, antithrombotic research has mostly been limited to research on hemolysis, anticoagulation mechanism and thrombus formation, and little research has been done on the relationship between inflammation, vascular endothelial cells and the pathological process of thrombus

Images